Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Insmed Inc

Healthcare US INSM

104.54USD
0.68(0.65%)

Last update at 2026-06-04T15:31:00Z

Day Range

102.89105.28
LowHigh

52 Week Range

18.7750.10
LowHigh

Fundamentals

  • Previous Close 103.86
  • Market Cap7141.96M
  • Volume480412
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-671.89498M
  • Revenue TTM315.49M
  • Revenue Per Share TTM2.20
  • Gross Profit TTM 190.23M
  • Diluted EPS TTM-5.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -480.15100M -436.41200M -292.68800M -253.56000M -324.07600M
Minority interest - - - - -
Net income -481.53400M -434.65400M -294.09000M -254.33700M -324.27700M
Selling general administrative 244.98M 234.27M 203.61M 210.80M 168.22M
Selling and marketing expenses 20.80M - - - -
Gross profit 190.23M 144.31M 124.54M 112.25M 7.41M
Reconciled depreciation 10.33M 14.18M 14.15M 10.18M 4.83M
Ebit -478.12300M -367.76000M -265.23200M -235.24500M -306.73600M
Ebitda -458.20700M -373.37200M -259.82400M -230.78300M -305.48700M
Depreciation and amortization 19.92M -5.61200M 5.41M 4.46M 1.25M
Non operating income net other 3.62M -20.84500M 2.11M 9.39M 8.73M
Operating income -478.12300M -367.76000M -265.23200M -235.24500M -307.33800M
Other operating expenses 723.48M 556.22M 429.64M 371.71M 317.17M
Interest expense 26.45M 40.47M 29.56M 27.70M 25.47M
Tax provision 1.38M -1.75800M 1.40M 0.78M 0.20M
Interest income - - - 17.78M 15.13M
Net interest income -26.44600M -40.47300M -29.56400M -27.70500M -25.47200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.38M -1.75800M 1.40M 0.78M 0.20M
Total revenue 245.36M 188.46M 164.41M 136.47M 9.84M
Total operating expenses 668.36M 512.07M 389.77M 347.50M 314.75M
Cost of revenue 55.13M 44.15M 39.87M 24.21M 2.42M
Total other income expense net -2.02800M -68.65200M -27.45600M -18.31500M 8.73M
Discontinued operations - - - - -
Net income from continuing ops -481.53400M -434.65400M -294.09000M -254.33700M -324.27700M
Net income applicable to common shares -481.53400M -434.65400M -294.09000M -254.33700M -324.27700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1329.84M 1656.43M 1243.51M 796.15M 742.30M
Intangible assets 63.70M 68.76M 73.81M 49.26M 53.68M
Earning assets - - - - -
Other current assets 24.18M 25.47M 28.90M 23.98M 20.22M
Total liab 1661.76M 1568.48M 833.04M 520.27M 480.62M
Total stockholder equity -331.92300M 87.95M 410.47M 275.88M 261.67M
Deferred long term liab - 37.59M 72.04M 47.29M 52.14M
Other current liab 214.99M 131.66M 89.25M 63.40M 0.28M
Common stock 1.48M 1.36M 1.19M 1.03M 0.90M
Capital stock 1.48M 1.36M 1.19M 1.03M 0.90M
Retained earnings -3446.14500M -2696.57800M -2265.24300M -1830.58900M -1536.49900M
Other liab - 60.49M 95.74M 9.18M 10.61M
Good will 136.11M 136.11M 136.11M 49.26M 53.68M
Other assets - 113.69M 50.99M 70.05M 72.45M
Cash 482.37M 1074.04M 716.78M 532.76M 487.43M
Cash and equivalents - - - - -
Total current liabilities 225.63M 190.24M 135.17M 118.81M 85.24M
Current deferred revenue -65.39300M - - - 59.52M
Net debt 721.62M 103.83M -104.51400M -127.91400M -90.39100M
Short term debt 10.64M 8.13M 10.14M 12.56M 12.26M
Short long term debt - - - - -
Short long term debt total 1203.99M 1177.87M 612.27M 404.84M 397.04M
Other stockholder equity 3113.49M 2782.42M 2673.56M 2105.25M 1797.29M
Property plant equipment - 56.49M 52.95M 53.95M 60.18M
Total current assets 929.06M 1273.38M 837.04M 622.89M 555.19M
Long term investments - 0.00000M 50.04M - -
Net tangible assets - -116.91500M 200.55M 226.62M 207.99M
Short term investments 298.07M 74.24M - - -
Net receivables 41.19M 29.71M 24.35M 16.56M 19.23M
Long term debt 1155.31M 1125.25M 566.59M 356.32M 335.94M
Inventory 83.25M 69.92M 67.01M 49.59M 28.31M
Accounts payable 65.39M 50.46M 35.78M 42.85M 13.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.74500M 0.76M 0.97M 0.19M -0.01000M
Additional paid in capital - - - - -
Common stock total equity - 1.36M 1.19M 1.03M 0.90M
Preferred stock total equity - - - - -
Retained earnings total equity - -2696.57800M -2265.24300M -1830.58900M -1536.49900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 96.57M 76.10M 50.99M 26.77M 20.31M
Deferred long term asset charges - - - - -
Non current assets total 400.77M 383.05M 406.47M 173.26M 187.10M
Capital lease obligations 48.68M 52.62M 45.68M 48.52M 61.10M
Long term debt total - 1125.25M 566.59M 356.32M 335.94M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -34.58400M -50.29200M -6.82200M -42.26800M -14.81400M
Change to liabilities 50.01M -7.57500M 24.93M -3.24500M 33.80M
Total cashflows from investing activities -34.58400M -64.28500M -6.82200M -42.26800M -14.81400M
Net borrowings 332.22M 321.70M -0.93600M -0.93600M 377.93M
Total cash from financing activities 793.27M 612.55M 271.00M 285.28M 386.74M
Change to operating activities -35.29900M -25.43100M -14.26900M -23.00500M 24.41M
Net income -481.53400M -434.65400M -294.09000M -254.33700M -324.27700M
Change in cash 357.25M 184.03M 45.33M -7.64300M 113.91M
Begin period cash flow 716.78M 532.76M 487.43M 495.07M 381.17M
End period cash flow 1074.04M 716.78M 532.76M 487.43M 495.07M
Total cash from operating activities -400.43900M -363.30200M -219.34800M -250.64900M -257.97700M
Issuance of capital stock 292.15M 269.89M 245.87M 261.07M 0.00000M
Depreciation 10.33M 14.18M 14.15M 10.18M 4.83M
Other cashflows from investing activities - -6.70400M -0.58200M - -1.72400M
Dividends paid - - - - -
Change to inventory -1.71400M -17.45600M -21.18000M -21.28100M -7.03200M
Change to account receivables -6.42300M -8.11800M 2.67M -13.71700M -5.51500M
Sale purchase of stock 311.66M 291.92M 271.94M 280.77M 8.81M
Other cashflows from financing activities 501.12M 567.66M 26.07M 24.20M 444.58M
Change to netincome 46.26M 71.04M 36.16M 26.97M 28.45M
Capital expenditures 9.88M 7.29M 6.82M 42.27M 14.81M
Change receivables -6.42300M -8.11800M 2.67M -13.71700M -5.51500M
Cash flows other operating -21.36300M 19.27M 16.62M 3.38M -5.51400M
Exchange rate changes - - 0.49M -0.00400M -0.04500M
Cash and cash equivalents changes 358.25M 184.96M 45.33M -7.64300M 113.91M
Change in working capital 6.58M -58.58000M -2.95400M -62.96900M 15.74M
Stock based compensation 57.69M 46.02M 36.16M 26.97M 26.24M
Other non cash items 6.50M 52.04M 27.39M 29.50M 17.29M
Free cash flow -410.31700M -370.59100M -226.17000M -292.91700M -272.79100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
INSM
Insmed Inc		 0.68 0.65% 104.54 - - 13.26 25.45 14.66 -6.7757
NVO
Novo Nordisk A/S		 2.31 5.51% 44.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 14.76 3.44% 443.10 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.86 1.11% 625.81 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Inc

700 US Highway 202/206, Bridgewater, NJ, United States, 08807

Key Executives

Name Title Year Born
Mr. William H. Lewis J.D., M.B.A. Pres, CEO & Chairman 1969
Ms. Sara M. Bonstein MBA Chief Financial Officer 1981
Mr. Roger Adsett Chief Operating Officer 1969
Ms. S. Nicole Schaeffer Chief People Strategy Officer 1968
Dr. Martina Flammer M.B.A., M.D. Chief Medical Officer 1964
Mr. John Goll III Sr. VP & Chief Accounting Officer NA
Eleanor Barisser Associate Director of Investor Relations NA
Mr. Michael Alexander Smith Sr. VP & Gen. Counsel 1978
Mandy Fahey Exec. Director of Corp. Communications NA
Mr. John Drayton Wise Sr. VP, Head of United States & Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions